Also found in: Dictionary, Wikipedia.


a platelet inhibitor and coronary vasodilator, used to prevent clotting associated with mechanical heart valves and to treat transient ischemic attacks. It is also used as an adjunct in the prevention of myocardial reinfarction and as an adjunct in radionuclide myocardial perfusion imaging.


Apo-Dipyridamole FC (CA), Apo-Dipyridamole SC (CA), Persantin (UK), Persantine

Pharmacologic class: Platelet adhesion inhibitor

Therapeutic class: Antiplatelet agent, diagnostic agent (coronary vasodilator)

Pregnancy risk category B


Unclear. May reduce platelet aggregation by inhibiting phosphodiesterase, adenosine uptake, or formation of thromboxane A2.


Tablets: 25 mg, 50 mg, 75 mg

Indications and dosages

To prevent thromboembolism in patients with prosthetic heart valves

Adults: 75 to 100 mg P.O. q.i.d.

Off-label uses

• Prevention of myocardial reinfarction (given with aspirin)
• Thrombotic thrombocytopenia purpura


• Hypersensitivity to drug


Use cautiously in:
• hypotension, hepatic insufficiency, severe coronary artery disease
• pregnant or breastfeeding patients
• children younger than age 12 (safety not established).


• Know that drug is usually given with warfarin when used to prevent thromboembolism.
• Give with a full glass of water at least 1 hour before or 2 hours after meals. If gastric distress occurs, give with food.

Adverse reactions

CNS: dizziness, headache

CV: hypotension

GI: abdominal distress

Hepatic: hepatic failure

Skin: rash


Drug-drug.Adenosine: increased adenosine plasma level and CV effects

Cholinesterase inhibitors: counteracts activity of cholinesterase inhibitors

Drug-diagnostic tests.Hepatic enzymes: increased levels

Drug-behaviors.Alcohol use: increased risk of hypotension

Patient monitoring

• Monitor for therapeutic efficacy, including improved exercise tolerance and decreased need for nitrates.
• Assess platelet and coagulation studies regularly.
• Monitor ECG and vital signs, especially blood pressure.
• Monitor hepatic function tests regularly.

Patient teaching

• Advise patient to take drug 1 hour before or 2 hours after meals for best absorption.

Instruct patient to immediately report unusual tiredness, chest pain or other cardiac symptoms, upper right abdominal pain, yellowing of skin or eyes, or dark urine.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


/di·py·rid·a·mole/ (di″pĭ-rid´ah-mōl) a platelet inhibitor and coronary vasodilator used to prevent thromboembolism associated with mechanical heart valves, to treat transient ischemic attacks, and as an adjunct in preventing myocardial reinfarction and in myocardial perfusion imaging.


(dī-pĭr′ĭ-də-mōl′, dī′pə-rĭd′ə-mōl′)
A drug, C24H40N8O4, that acts as a coronary vasodilator and is used in the long-term treatment of angina pectoris and as an antiplatelet agent.


an antiplatelet agent.
indication When used in combination with coumarin anticoagulants, it is used to prevent postoperative thromboembolic complications of cardiac valve replacement.
contraindications It should be used with caution in hypotension.
adverse effects The adverse reactions are mild and transient, such as headache, dizziness, rash, nausea, and flushing.


A drug used to reduce platelet stickiness and thus the risk of STROKE in people having TRANSIENT ISCHAEMIC ATTACKS. Aspirin is more effective, but sometimes cannot be safely taken. A brand name is Persantin.

antiplatelet therapy

agents that reduce platelet aggregation and inhibit arterial thrombus formation in an area of the circulation where other anticoagulants have reduced effect; e.g. low-dose aspirin (75 mg daily), clopidogrel (± low-dose aspirin), dipyridamole (used to prevent thromboembolism in patients with prosthetic heart valves), abciximab, eptifibatide and tirofiban


n brand name: Persantine;
drug class: platelet aggregation inhibitor;
action: specific action unclear; inhibits ability of platelets to aggregate;
uses: prevention of transient ischemic attacks (TIA), inhibition of platelet aggregation to prevent myocardial reinfarction, prevention of coronary bypass graft occlusion with aspirin.


a coronary vasodilator with antiplatelet activity.
References in periodicals archive ?
Early secondary prevention with Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA* [25mg]) is at least as effective and safe as initial treatment with ASA 100 mg alone after an ischaemic stroke or transient ischaemic attack (TIA).
showed increased cumulative rates of death and myocardial infarction in proportion to summed stress score (SSS) severity in 367 patients undergoing dipyridamole Rb-82 PET MPI.
Results of this meta-analysis demonstrated that for patients with PAD, aspirin therapy alone or in combination with dipyridamole did not significantly decrease the primary end point of cardiovascular events, results that may reflect limited statistical power," wrote the authors.
INGELHEIM AM RHEIN, Germany, January 23 /PRNewswire/ -- The latest results from ESPRIT (European/Australasian Stroke Prevention in Reversible Ischaemia Trial), published in the February 2007 issue of Lancet Neurology, confirm that the combination of dipyridamole plus aspirin is the treatment of choice for secondary stroke prevention in patients with stroke of arterial origin.
Concomitant administration with specific phosphodiesterase-5 (PDE-5) inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (such as dipyridamole or theophylline).
The anticoagulation regimen for patients receiving a Heart-Mate II device consisted of warfarin, dipyridamole, and aspirin.
A new synergistic drug candidate CRx-102, a combination of dipyridamole and low dose prednisolone, was assessed for its efficacy and safety in patients with hand OA in a blinded, RCT.
Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, Cunha A, Souza DO, Zarate CAJr, Kapczinski F A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania.
These patients are typically treated with aspirin and dipyridamole to prevent thrombosis.
Supportively, ENT inhibition using the broad ENT inhibitors dilazep or dipyridamole attenuated basal thymidine uptake by 85.
Intravenous immunoglobulin 2 g/kg/day 12 hours of infusion, aspirin 80 mg/kg/day in 4 doses and dipyridamole 6 mg/kg/day in 3 doses was started.